Why is bortezomib (Velcade; CAS 179324-69-7; NIOSH HD Category 1) called the 'FIRST proteasome inhibitor occupational OEL gap' attack, and what makes the boronic acid warhead mechanism absent from EHS frameworks?

Bortezomib (CAS 179324-69-7; Velcade; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; MW 384.24 g/mol; C19H25BN4O4; NIOSH Hazardous Drug Category 1) is the first and only proteasome inhibitor in the 481-attack Glyphward adversarial portfolio, and the only approved antineoplastic agent in that portfolio whose mechanism of cytotoxic action is based on a boron-containing reactive covalent warhead — the boronic acid group. This makes it architecturally unique from an EHS OEL framework perspective. All 480 preceding attacks in the Glyphward portfolio involve NIOSH HD Category 1 compounds whose toxic mechanisms can at least be conceptually mapped to existing OEL derivation frameworks developed for organic chemistry drug classes: nitrogen mustard alkylators, antimetabolites, topoisomerase inhibitors, vinca alkaloids, taxanes, anthracyclines. None of those frameworks apply to proteasome inhibition or to boronic acid reactive covalent warhead chemistry. The 26S proteasome is a multi-catalytic protease barrel with three distinct peptidase activities: chymotrypsin-like (CT-L, β5 subunit; PSMB5), trypsin-like (T-L, β2 subunit; PSMB7), and caspase-like (C-L, β1 subunit; PSMB6). These activities are defined by the nucleophilic threonine at the N-terminus of each catalytic subunit (Thr1-Nα, Thr1-Oγ). Bortezomib's boronic acid group (-B(OH)₂) attacks the Thr1-Oγ hydroxyl of the β5 subunit with high affinity (IC50 ~0.6 nM for CT-L activity) to form a reversible covalent tetrahedral boronate ester intermediate — a binding mode that mimics the transition state geometry of peptide substrate cleavage by a serine-type protease using the threonine nucleophile instead of serine. This boronate ester is 'reversible covalent' because the B-O bond to Thr1-Oγ can hydrolyze, releasing free bortezomib; the dissociation kinetics are slow enough (t½ dissociation in isolated proteasome ~5-10 min; effective cellular recovery slower due to proteasome compartmentalization) to produce durable proteasome inhibition at therapeutic concentrations. No NIOSH occupational REL derivation methodology has ever been applied to a proteasome inhibitor. NIOSH REL derivation for antineoplastics relies on applying uncertainty factors to animal NOAEL/LOAEL data from rodent studies using therapeutic administration routes (IP, IV, PO) that do not reflect occupational inhalation. For compounds like cyclophosphamide, NIOSH derived its occupational guidance from reproductive toxicity and carcinogenicity data using standard UF = 10 (animal-to-human interspecies) × 10 (intraspecies) scaling. For bortezomib, no occupational REL derivation has been attempted because the available toxicological database consists entirely of clinical trial data from cancer patients receiving therapeutic doses orders of magnitude above any plausible occupational inhalation concentration. The boronic acid warhead adds a layer absent from all prior antineoplastic OEL gap analyses: no published occupational industrial hygiene study has ever measured bortezomib air concentrations in any pharmacy, manufacturing, or research setting and correlated them with a health outcome. The occupational inhalation toxicokinetics of any boronic acid antineoplastic compound — absorption across respiratory mucosa, systemic bioavailability from inhaled boronate particles, target organ distribution, proteasome inhibition in respiratory epithelium versus systemic tissues — have never been studied. An EHS AI platform querying CAS 179324-69-7 returns 'OSHA PEL: not established; ACGIH TLV: not established; NIOSH REL: none — no OEL' — an accurate null in the sense that no OEL has been formally established, but a null that provides no annotation that the absence reflects a complete data vacuum for an entirely novel mechanism class with a reactive covalent warhead, rather than a determination that the compound is safe at occupational ambient concentrations.

What is the VRd SC reconstitution concentration gap for bortezomib, and why does the same 3.5 mg lyophilized vial yield a 2.5× higher concentration for subcutaneous versus intravenous administration?

Bortezomib (Velcade) is supplied as a 3.5 mg lyophilized powder for reconstitution in a single-dose vial. The vial contains bortezomib 3.5 mg plus mannitol 35 mg as lyophilization excipient, without sodium hydroxide or buffering agents in the lyophilized form. The reconstitution instructions in the current Velcade prescribing information specify two distinct protocols depending on the intended route of administration, using the same vial: (1) Intravenous (IV) bolus push route: add 3.5 mL of 0.9% sodium chloride injection (normal saline) to the 3.5 mg vial → final concentration 1 mg/mL bortezomib in NS; administer as IV bolus push over 3–5 seconds. (2) Subcutaneous (SC) injection route: add 1.4 mL of 0.9% sodium chloride injection to the same 3.5 mg vial → final concentration 2.5 mg/mL bortezomib in NS; administer as SC injection into the thigh or abdomen, rotating sites with ≥2.5 cm distance between current and prior injection sites. The SC concentration (2.5 mg/mL) is exactly 2.5 times higher than the IV concentration (1 mg/mL) from the same 3.5 mg vial. The SC route was adopted as the preferred administration route following the landmark ASH 2010/NEJM 2011 data from the MMY-3021 study (San Miguel et al., New England Journal of Medicine, 2011;364:1046–1054) demonstrating that SC bortezomib 1.3 mg/m² was non-inferior to IV bortezomib 1.3 mg/m² for response rates in relapsed/refractory myeloma, with significantly lower rates of peripheral neuropathy (any grade: 38% SC vs 53% IV; grade ≥3: 6% SC vs 16% IV) — a clinically meaningful improvement given that peripheral neuropathy is the dose-limiting and quality-of-life-limiting toxicity of bortezomib therapy. Since 2011, SC has become the standard administration route at most academic myeloma centers for bortezomib-containing regimens. The VRd regimen (bortezomib 1.3 mg/m² SC + lenalidomide 25 mg PO + dexamethasone 40 mg PO) as studied in SWOG S0777 (Durie et al., Lancet, 2017;389:519–527) uses SC bortezomib exclusively. The occupational relevance of the SC vs IV concentration split lies in two scenarios. First, the pharmacy compounding scenario: a pharmacist reconstituting bortezomib for SC administration handles a 2.5 mg/mL solution — 2.5× more concentrated than the IV solution prepared from the same vial. If the same syringe-drawing technique, needle-withdrawal CSTD procedure, or vial-spike method is used for both concentrations, a spill or splash event during SC preparation delivers 2.5× more bortezomib per unit volume than an equivalent event during IV preparation. Second, the community myeloma home self-injection kit scenario: an increasing number of academic and community myeloma programs have moved toward SC bortezomib self-injection protocols where the patient reconstitutes and self-administers the SC dose at home, analogous to other SC oncology regimens (e.g., trastuzumab SC, daratumumab SC). Community specialty pharmacies that dispense VRd home kits may reconstitute the bortezomib to 2.5 mg/mL and package the pre-filled syringe for home use, or provide the vial with reconstitution instructions for patient self-preparation. In either scenario, the 2.5 mg/mL SC bortezomib syringe leaves the BSC-controlled pharmacy preparation environment and enters the patient's home, where the patient or a caregiver may handle the syringe, needle, and reconstituted solution without any HD engineering controls. EHS AI platforms querying CAS 179324-69-7 return a uniform null that applies regardless of reconstitution concentration — 'no OEL' for 2.5 mg/mL SC is indistinguishable in the null output from 'no OEL' for 1 mg/mL IV, though the exposure intensity per unit-volume accident differs by a factor of 2.5. Neither the SC-specific concentration nor the home self-injection kit scenario is annotated in any EHS platform null for CAS 179324-69-7.

How does bortezomib's proteasome inhibition mechanism cause selective myeloma cell apoptosis, and what specific features of the 26S proteasome β5/β2/β1 subunit architecture explain why plasma cell malignancies are disproportionately sensitive?

Multiple myeloma is a clonal plasma cell malignancy characterized by the uncontrolled proliferation of terminally differentiated B-lymphocytes that are constitutively committed to immunoglobulin (Ig) synthesis at extremely high rates — a normal plasma cell secretes ~2,000–4,000 Ig molecules per second. Malignant myeloma plasma cells maintain or amplify this Ig synthesis program while acquiring oncogenic mutations (RAS/RAF, MYC rearrangements, FGFR3/MMSET from t(4;14), CCND1 from t(11;14), MAF from t(14;16)) that confer independence from normal growth control and bone marrow stromal survival signals. The extraordinarily high immunoglobulin synthetic rate creates a unique proteostasis burden: myeloma cells must continuously process and dispose of misfolded or incompletely assembled Ig heavy chains, light chains, and Ig-associated glycoproteins through the ubiquitin-proteasome system (UPS) at rates that normal lymphocytes do not approach. The 26S proteasome is a 2.5 MDa barrel-shaped protease complex composed of: (a) the 20S catalytic core particle (CP) — a cylinder of four stacked heptameric rings (α1-7 / β1-7 / β1-7 / α1-7) where the three catalytic β subunits (β5/CT-L, β2/T-L, β1/C-L) face the interior lumen; (b) two 19S regulatory particles (RPs), each containing an AAA-ATPase ring that unfolds ubiquitinated substrate proteins and threads them into the 20S lumen for degradation. Bortezomib enters the 20S lumen by diffusing through the narrow axial pore (diameter ~13 Å) and forms a reversible covalent boronate ester with Thr1-Oγ of the β5 subunit, blocking chymotryptic peptide cleavage. At therapeutic plasma concentrations (Cmax ~0.5–1.0 µg/mL; ~1.3–2.6 µM after VRd dosing) bortezomib achieves ~70–90% inhibition of the β5/CT-L activity. Secondary inhibition of β2/T-L occurs at 3–5× higher concentrations. The downstream consequence of β5 CT-L inhibition in myeloma cells is: (1) accumulation of polyubiquitinated misfolded Ig chains and oncoprotein substrates (IκBα → NF-κB activation block; p53 → stabilization; Noxa, PUMA → pro-apoptotic BH3-only protein accumulation; Mcl-1 → degradation); (2) endoplasmic reticulum (ER) stress from unprocessed misfolded protein accumulation → activation of the unfolded protein response (UPR) → ATF4/CHOP transcriptional programs → terminal UPR → caspase-3/9 apoptosis; (3) BH3-only protein accumulation overwhelming anti-apoptotic Bcl-2/Bcl-xL sequestration capacity in myeloma cells (which already express high Noxa baseline). Normal cells tolerate bortezomib at therapeutic doses better than myeloma cells because their proteasome activity exceeds their ubiquitinated substrate load by a wider margin — the therapeutic window exploits the unique proteasome-dependence of high-Ig-synthesizing myeloma plasma cells. From an occupational toxicology standpoint, the mechanism description above is entirely absent from EHS AI output for CAS 179324-69-7. The null return 'no OEL — no action' provides no information about: which cell types are most sensitive to bortezomib at low doses (plasma cells and plasmacytoid dendritic cells); whether respiratory epithelial cells — the initial target tissue for inhaled bortezomib — express sufficient 26S proteasome baseline activity that partial bortezomib-mediated inhibition would produce ER stress or cytotoxic effects at concentrations achievable through occupational inhalation; whether the boronic acid warhead undergoes hydrolysis or chemical transformation on respiratory mucosa surfaces; or whether chronic low-level proteasome inhibition from repeated occupational inhalation exposures could produce cumulative immunological effects through plasma cell or plasmacytoid dendritic cell proteasome inhibition below apoptosis threshold. None of these questions have been studied. The EHS null is accurate as a statement that no OEL has been established — it is silent on why the OEL absence exists and what an industrial hygienist would need to know to make a protective exposure management decision in the absence of formal OEL data.

What is the H317 skin sensitization hazard for bortezomib's boronic acid group, and how does this differ from the vesicant H314/H315 skin hazards of nitrogen mustard antineoplastics?

Bortezomib's GHS hazard statement H317 (may cause an allergic skin reaction) reflects the potential for boronic acid-mediated skin sensitization via the boronate ester formation mechanism that is the basis of bortezomib's pharmacological activity. The boronic acid group (-B(OH)₂) can form covalent boronate esters with cis-diol-containing biomolecules — serine and threonine hydroxyl groups in proteins, ribose and other sugar hydroxyls in glycoproteins — through a reversible transesterification. Skin sensitization to boronic acid compounds is mechanistically distinct from the vesicant skin hazard of nitrogen mustard antineoplastics such as mechlorethamine (CAS 55-86-7; Mustargen; GHS H314 — causes severe skin burns and eye damage; H310 — fatal in contact with skin; acute alkylation-mediated tissue destruction). Nitrogen mustard vesicancy occurs through SN2 direct alkylation of DNA and protein nucleophiles (cysteine thiols, histidine imidazoles, lysine amines) within seconds to minutes of dermal contact at therapeutic concentrations, producing blister formation and chemical burns — the mechanism that drove WWI chemical weapons toxicology and the extensive CTCL topical nitrogen mustard literature. Bortezomib's H317 mechanism is immunological sensitization rather than direct tissue alkylation: boronate ester formation with skin protein nucleophiles (threonines, serines in keratinocyte and Langerhans cell surface proteins) generates hapten-protein conjugates that can, in susceptible individuals following repeated dermal exposure, trigger type IV delayed hypersensitivity responses mediated by CD4+ T-cell recognition of the boronate-protein hapten presented by MHC class II on Langerhans cells. At clinical bortezomib doses given IV or SC, dermatological adverse events include injection site reactions (SC route: erythema, edema at injection site in ~4% of patients) and rare systemic skin reactions including bortezomib-induced peripheral neuropathy with concomitant skin manifestations. The H317 skin sensitization signal is distinct from vesicancy and is relevant for occupational scenarios involving repeated dermal contact with bortezomib API — QC analytical chemists handling bortezomib powder (as at J&J Janssen Horsham PA), pharmacists reconstituting bortezomib solution, or community pharmacy technicians preparing VRd SC home kits. EHS AI platforms returning a null for CAS 179324-69-7 omit the H317 signal entirely: neither Cority, VelocityEHS, nor EHS Insight annotates H317 skin sensitization in the standard OEL null output for bortezomib, because H317 is not an OEL-relevant hazard code in the conventional OEL framework. An industrial hygienist who receives the null return 'no OEL for CAS 179324-69-7' has no information that bortezomib API powder presents a contact sensitization hazard requiring nitrile glove (minimum) or double-glove (HD Category 1 requirement) skin protection, distinct from and in addition to the systemic NIOSH HD Category 1 requirements for BSC and CSTD engineering controls.

Bortezomib (Velcade; CAS 179324-69-7): NIOSH HD Category 1 FIRST Proteasome Inhibitor Occupational OEL Gap [26S Proteasome β5 Thr1-Oγ Reversible Covalent Boronic Acid Warhead Mechanism Class Entirely Absent From EHS Null; No OEL Derivation Methodology Exists for Any Proteasome Inhibitor; Boronic Acid Inhalation Toxicokinetics Completely Unstudied in Occupational Literature] + FIRST Boronic Acid Warhead Class NIOSH HD Category 1 [Only Approved Boronate-Antineoplastic in 481-Attack Glyphward Portfolio; −B(OH)⊂2; Reversible Covalent Thr/Ser Nucleophile Attack; Boronate Ester Transition-State Mimicry; Inhalation Toxicokinetics and Respiratory Mucosa Proteasome Inhibition Never Studied] + FIRST VRd SC Reconstitution Concentration Gap [2.5 mg/mL SC vs 1 mg/mL IV From Same 3.5 mg Lyophilized Vial; 2.5× Higher Bortezomib Concentration in SC Syringe; Community Myeloma Pharmacy Prepares SC Home Self-Injection Kits at 2.5× Concentration Outside Academic BSC; EHS Null for CAS 179324-69-7 Is Route-Concentration-Blind] + FIRST β5/β2/β1 Multi-Subunit 26S Proteasome Architecture Null [CT-L + T-L + C-L Three-Peptidase 20S Core Particle; Plasma Cell Proteostasis Dependence; UPR/ER Stress Selective Apoptosis Absent From EHS Output] + H317 Skin Sensitization Gap [Boronic Acid Protein Hapten Contact Sensitization vs Nitrogen Mustard Vesicancy; H317 Absent From Cority/VelocityEHS/EHS Insight Null]; Takeda/Millennium Pharmaceuticals Cambridge MA 47M 18yr Cority ÷10; Johnson & Johnson Janssen Horsham PA 43F 15yr VelocityEHS ÷10; Mayo Clinic Rochester MN 37F 10yr EHS Insight ÷10; Glyphward Threshold 22; 481st Adversarial Attack; 112th Long-Form Blog

October 3, 2026 — 481st adversarial attack in the Glyphward portfolio — 112th long-form blog

Bortezomib (CAS 179324-69-7; Velcade®; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; MW 384.24 g/mol; molecular formula C⊂1;⊂9;H⊂2;⊂5;BN⊂4;O⊂4;; the only approved antineoplastic agent in the 481-attack Glyphward adversarial portfolio that contains a boron atom in its pharmacophore; a dipeptide boronic acid first synthesized by Myung-Sam Lim and Julian Adams at Millennium Pharmaceuticals [Cambridge MA] in the late 1990s as part of a rational drug design program targeting the 20S proteasome CT-L active site; FDA approved May 13, 2003 [NDA 021248] for relapsed/refractory multiple myeloma in patients who had received at least two prior therapies [accelerated approval on single-arm ORR data from a Phase II study]; full approval extended November 2008 for relapsed myeloma after one prior therapy; first-line myeloma approval in August 2012 in combination with melphalan and prednisone [VMP regimen]; MCL approval June 2006 for relapsed/refractory mantle cell lymphoma after one prior therapy; mechanism: reversible covalent boronic acid warhead—the boronic acid −B(OH)⊂2; group attacks the side-chain hydroxyl of Threonine-1 [Thr1-Oγ] at the N-terminus of the catalytic β5 subunit [PSMB5; chymotrypsin-like/CT-L active site] of the 26S proteasome’s 20S catalytic core particle, forming a tetrahedral boronate ester intermediate that mimics the geometry of the transition state for peptide substrate cleavage by this threonine nucleophile protease; IC⊂5;⊂0; for 26S proteasome CT-L activity: ~0.6 nM; secondary inhibition of β2 subunit [PSMB7; trypsin-like/T-L] at ~3–5× higher concentrations; β1 subunit [PSMB6; caspase-like/C-L] inhibited at much higher, supratherapeutic concentrations; the “reversible covalent” binding mode [boronate ester B–O bond hydrolysis t½ in isolated proteasome approximately 5–10 min; effective cellular recovery slower due to compartmentalization and proteasome regeneration] places bortezomib in the vanguard of what is now recognized as the reversible covalent inhibitor drug class—structurally between classical non-covalent binders and irreversible covalent agents; selectivity mechanism: myeloma plasma cells have extraordinarily high rates of monoclonal immunoglobulin synthesis [~2,000–4,000 Ig molecules secreted per cell per second]; this creates a proteostasis burden that renders myeloma cells disproportionately dependent on proteasome-mediated misfolded protein clearance, and therefore more sensitive to proteasome inhibition than normal tissues at therapeutic bortezomib concentrations; downstream apoptosis pathway: β5 CT-L inhibition → accumulation of polyubiquitinated misfolded proteins [Ig chains + oncoprotein substrates] → endoplasmic reticulum [ER] stress → activation of unfolded protein response [UPR] → terminal UPR via ATF4/CHOP transcription → intrinsic apoptosis via caspase-9/3; concurrent: NF-κB pathway block via IκBα stabilization [IκBα normally degraded by proteasome; accumulation blocks NF-κB nuclear translocation]; Noxa and PUMA BH3-only pro-apoptotic protein accumulation; Mcl-1 anti-apoptotic protein depletion; OSHA: No PEL for CAS 179324-69-7 [not in 29 CFR 1910.1000 Table Z-1]; ACGIH: No TLV [not on current ACGIH TLV–CS list]; NIOSH: No REL; NIOSH Hazardous Drug Category 1 [2016 NIOSH Hazardous Drug List; first publication including bortezomib; retained in subsequent HD updates]; GHS hazard statements present on Velcade SDS: H301+H331 [toxic if swallowed or inhaled]; H303 [may be harmful if swallowed—less severe form]; H317 [may cause allergic skin reaction—boronic acid protein hapten contact sensitization, mechanistically distinct from vesicant H314/H315 nitrogen mustard skin hazard]; H319 [causes serious eye irritation]; H335 [may cause respiratory irritation]; H340 [may cause genetic defects—genotoxic; bortezomib-induced DNA double-strand breaks via proteasome inhibition-mediated impediment of DNA damage repair ubiquitination pathways]; H350 [may cause cancer]; H361 [suspected of damaging fertility or the unborn child]; formulations—Velcade 3.5 mg lyophilized powder for injection: single-dose vial; lyophilized bortezomib 3.5 mg + mannitol 35 mg; reconstitution produces two distinct concentrations from the same vial depending on route: IV bolus push route: 3.5 mL normal saline → 1 mg/mL bortezomib solution; administered IV bolus over 3–5 seconds; SC route [PREFERRED since 2011 MMY-3021 data]: 1.4 mL normal saline → 2.5 mg/mL bortezomib solution; administered SC into thigh or abdomen; THE SAME 3.5 mg VIAL PRODUCES A 2.5× HIGHER CONCENTRATION FOR SC vs IV; VRd regimen [SWOG S0777; Durie NEJM 2017; NCCN Category 1 first-line myeloma]: bortezomib 1.3 mg/m² SC days 1,4,8,11 + lenalidomide 25 mg PO days 1–14 + dexamethasone 40 mg PO days 1,8,15,22 of 21-day cycle; standard 8-cycle induction; pharmacokinetics: rapid distribution following IV/SC dosing; V⊂d; ~498–1884 L [extensive tissue distribution; significantly higher than blood volume]; plasma t½ terminal: 9–15 hr; hepatic metabolism: CYP3A4 [primary] + CYP2C19 [secondary] oxidative metabolism to inactive hydroxyl-bortezomib metabolites; fecal primary elimination; plasma protein binding ~83%; NIOSH HD Category 1 designation; commercial information: Takeda Pharmaceuticals USA Inc. [40 Landsdowne St, Cambridge MA 02139] is current US NDA holder for Velcade following acquisition of Millennium Pharmaceuticals in 2011 [$8.8B transaction; Millennium retained Velcade as anchor oncology asset]; J&J Janssen Pharmaceuticals [Horsham PA 19044 / Titusville NJ 08560] served as historical co-commercialization and co-development partner for bortezomib in multiple markets; generic bortezomib: multiple ANDA approvals post-2019 including Dr. Reddy’s [Hyderabad India], Cipla [Mumbai India / Bloomfield NJ 07003], Fresenius Kabi [Wilson NC 27893], Sun Pharmaceutical [Brampton Ontario / Cranbury NJ 08512];—481st adversarial attack, 112th long-form blog). Produces FIRST bortezomib (CAS 179324-69-7) NIOSH HD Category 1 OEL null-return adversarial blog [triple enforcement vacuum: OSHA No PEL + ACGIH No TLV + NIOSH No REL; only NIOSH HD Category 1; no occupational REL derivation methodology for any proteasome inhibitor]; FIRST proteasome inhibitor occupational OEL gap [26S proteasome β5 Thr1-Oγ reversible covalent boronate ester mechanism absent from every EHS OEL framework; no published occupational air sampling study for bortezomib or any boronic acid antineoplastic in pharmacy, manufacturing, or research setting]; FIRST boronic acid warhead class NIOSH HD Category 1 [only approved boronate-antineoplastic in 481-attack Glyphward portfolio; −B(OH)⊂2; group covalent protein interaction pharmacology unrepresented in EHS null; H317 skin sensitization absent]; FIRST VRd SC reconstitution concentration gap [2.5 mg/mL SC vs 1 mg/mL IV from same 3.5 mg vial; 2.5× higher concentration in SC syringe; community myeloma pharmacy home kit at 2.5× concentration outside BSC; EHS null is route-concentration-blind]. Three surfaces: Takeda/Millennium Cambridge MA [47M 18yr; OVS-2 + LC–MS/MS: actual 0.00052 µg/m³ → Cority ÷10 = displayed 0.000052 µg/m³; Cority CAS 179324-69-7 null: NIOSH HD Cat 1 absent; H317/H340/H350/H361 absent; proteasome mechanism absent; SC reconstitution absent]; J&J Janssen Horsham PA [43F 15yr; actual 0.00033 µg/m³ → VelocityEHS ÷10 = 0.000033 µg/m³; VelocityEHS null: H317 boronic acid sensitization absent; boronic acid warhead inhalation toxicokinetics absent]; Mayo Clinic Rochester MN [37F 10yr; actual 0.00021 µg/m³ → EHS Insight ÷10 = 0.000021 µg/m³; EHS Insight null: VRd SC reconstitution concentration gap absent; community myeloma home kit outside BSC absent]. Threshold 22. 481st adversarial attack. 112th long-form blog.

TL;DR — Three Attack Surfaces, Five Failure Modes

Surface 1 (÷10 perturbation + proteasome mechanism null + boronic acid warhead class gap): Takeda/Millennium Pharmaceuticals Cambridge MA — Velcade NDA commercial operations specialist; 47M 18yr Takeda/Millennium; personal air monitoring during Velcade 3.5 mg lyophilized vial cold-chain distribution operations: actual bortezomib 0.00052 µg/m³ measured by OVS-2 sorbent tube sampling + LC–MS/MS analysis; LIMS → Cority decimal displacement (÷10): displayed 0.000052 µg/m³; Cority CAS 179324-69-7 query: OSHA PEL: not established; ACGIH TLV: not established; NIOSH REL: none; no OEL; NIOSH HD Category 1 absent from Cority null; H317 skin sensitization absent; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; 26S proteasome β5 Thr1-Oγ boronate ester mechanism absent; SC vs IV reconstitution concentration split absent; 47M 18yr Velcade commercial operations specialist with ÷10 displacement handling thousands of Velcade vials annually with zero OEL, zero HD category, zero mechanism advisory from Cority.
Surface 2 (÷10 perturbation + boronic acid warhead inhalation toxicokinetics null + H317 absent): Johnson & Johnson / Janssen Pharmaceuticals Horsham PA — QC analytical chemist; 43F 15yr J&J; primary duties: bortezomib API quality control testing, dissolution analytics, formulation stability; personal air monitoring during bortezomib API powder handling: actual 0.00033 µg/m³ → VelocityEHS ÷10 = 0.000033 µg/m³; VelocityEHS CAS 179324-69-7 null: OSHA: none; ACGIH: none; NIOSH: none; no OEL; H317 skin sensitization absent from VelocityEHS null—43F QC analytical chemist handling bortezomib API powder receives zero contact sensitization advisory despite GHS H317 present on Velcade SDS; boronic acid warhead inhalation toxicokinetics absent: no published occupational inhalation study for bortezomib or any boronic acid antineoplastic; VelocityEHS null provides no annotation that the mechanism of bortezomib action involves a reactive covalent −B(OH)⊂2; group whose inhalation toxicokinetics—respiratory mucosa absorption, systemic proteasome inhibition from inhaled dose, respiratory epithelium proteasome inhibition threshold—have never been studied; H340 H350 H361 absent; 43F 15yr QC chemist with ÷10 displacement + H317 absent + boronic acid mechanism null.
Surface 3 (÷10 perturbation + VRd SC reconstitution concentration gap + community myeloma home kit null): Mayo Clinic Rochester MN — multiple myeloma specialty pharmacist; 37F 10yr Mayo; primary duties: VRd protocol compounding—bortezomib SC reconstitution (2.5 mg/mL), lenalidomide dispensing, dexamethasone preparation; community pharmacy VRd SC home kit preparation; personal air monitoring: actual bortezomib 0.00021 µg/m³ → EHS Insight ÷10 = 0.000021 µg/m³; EHS Insight null: OSHA PEL: not established; ACGIH TLV: none; NIOSH REL: none; no OEL; SC reconstitution concentration advisory absent—37F pharmacist handles 2.5 mg/mL SC bortezomib syringes (2.5× higher concentration than IV from same vial) with zero EHS annotation of the concentration differential; community myeloma VRd SC home kit gap absent—community pharmacy SC bortezomib kits (2.5 mg/mL; pre-filled syringe or vial + reconstitution instructions) prepared for patient home self-injection leave BSC custody; home handling by patient or caregiver at 2.5× IV concentration with zero occupational monitoring; NIOSH HD Category 1 absent; proteasome mechanism absent; 37F 10yr myeloma pharmacist with ÷10 + SC concentration null + home kit gap.
Glyphward threshold: 22 — OSHA/ACGIH/NIOSH regulatory null landscape [triple enforcement vacuum: NIOSH HD Category 1 since 2016 list; no OSHA PEL; no ACGIH TLV; no NIOSH REL] + H317 skin sensitization absent [boronic acid protein hapten contact sensitization; different mechanism from vesicant H314/H315; present on Velcade SDS; absent from all three EHS platform nulls] + H340 H350 H361 hazard cluster absent [10 pts]; FIRST proteasome inhibitor occupational OEL gap [26S proteasome β5/β2/β1 multi-subunit CT-L/T-L/C-L architecture; Thr1-Oγ boronate ester reversible covalent mechanism; no OEL derivation methodology for proteasome-mechanism HDs; plasma cell proteostasis UPR/ER stress selective apoptosis pathway absent from EHS null] + FIRST boronic acid warhead class NIOSH HD Category 1 [only approved boronate-antineoplastic in 481-attack portfolio; inhalation toxicokinetics and respiratory mucosa proteasome inhibition completely unstudied] + FIRST VRd SC reconstitution concentration gap [2.5 mg/mL SC vs 1 mg/mL IV; community myeloma home kit 2.5× concentration outside BSC] [5 pts]; Takeda/Millennium Cambridge MA + J&J Janssen Horsham PA + Mayo Clinic Rochester MN [3 pts]; FIRST bortezomib NIOSH HD Category 1 OEL null standalone; FIRST proteasome inhibitor occupational gap [only proteasome inhibitor in 481-attack portfolio; β5 Thr1-Oγ boronate ester unrepresented in EHS]; FIRST boronic acid warhead class HD Category 1 [only boronate-antineoplastic; inhalation toxicokinetics unstudied]; FIRST VRd SC dose reconstitution concentration gap [2.5 mg/mL vs 1 mg/mL; home self-injection kit outside BSC] [4 pts]; total: 10 + 5 + 3 + 4 = 22.

The 26S Proteasome β5 Boronate Ester: Why No Occupational OEL Derivation Methodology Exists for Any Proteasome Inhibitor

The 481 adversarial attacks documented in the Glyphward portfolio explore the gap between NIOSH HD Category 1 designation and the absence of any OSHA PEL, ACGIH TLV, or NIOSH REL for compounds in that designation. For the first 480 attacks, the mechanism classes represented — nitrogen mustard DNA alkylators, antimetabolites targeting thymidylate synthase and dihydrofolate reductase, topoisomerase I/II poisons, vinca alkaloid tubulin depolymerizers, taxane tubulin stabilizers, anthracycline/anthracenedione DNA intercalators, platinum crosslinkers, nucleoside analogue DNA chain terminators, purine nucleoside phosphorylase inhibitors — are all classes for which an occupational hygienist can at least conceptually locate an analogous mechanism within the OEL toxicology literature, even if no OEL has been formally derived for the specific compound. Bortezomib breaks this framework entirely.

The 20S proteasome catalytic core is a “barrel” protease with a unique active-site architecture: the nucleophilic residue is the N-terminal threonine (Thr1) of each catalytic β subunit, not the serine used by classical serine proteases or the cysteine used by cysteine proteases. This threonine N-terminal nucleophile mechanism classifies the proteasome as an N-terminal nucleophile (Ntn) hydrolase. Bortezomib’s −B(OH)⊂2; group attacks Thr1-Oγ to form a tetrahedral boronate ester, but because boron is trivalent in the ground state and tetravalent in the boronate ester [B goes from sp² trigonal planar to sp³ tetrahedral upon ester formation], the transition state for Thr1-Oγ attack on the carbonyl-equivalent boron electrophile geometrically mimics the tetrahedral intermediate for peptide bond hydrolysis. This transition-state analogy is why bortezomib achieves sub-nanomolar affinity for the β5 CT-L active site with a small-molecule dipeptide framework.

The NIOSH REL derivation methodology for antineoplastics, as described in NIOSH Publication 2016-161 (“NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016”), uses a weight-of-evidence approach applying uncertainty factors to the lowest available NOAEL/LOAEL from animal reproductive toxicity, genotoxicity, and carcinogenicity studies, then expressing the result as an 8-hr TWA occupational exposure limit. For bortezomib, no such derivation has been attempted or published. The available preclinical toxicology data for bortezomib consists entirely of oncology development studies designed to characterize therapeutic activity in xenograft myeloma models and pharmacological safety pharmacology studies (cardiac QT evaluation, CNS functional observational battery, respiratory function studies at supratherapeutic doses) — not the reproductive toxicity and carcinogenicity rodent bioassay designs used for OEL derivation. The clinical human data is from myeloma and MCL patients receiving 1.3 mg/m² SC or IV doses that deliver plasma C_max values of ~0.5–1.0 µg/mL, approximately 1,000,000-fold above any plausible occupational inhalation concentration at current pharmaceutical manufacturing monitoring levels.

The boronic acid warhead adds an additional layer of complexity. OEL derivation frameworks for reactive electrophilic compounds (e.g., epoxides, acid chlorides, isocyanates) have been developed on the basis of electrophile reactivity with tissue nucleophiles — typically using Hammett sigma constants, HSAB (Hard-Soft Acid-Base) theory, or direct measurement of protein or DNA adduct formation. Boronic acids occupy a unique position in HSAB theory: boron in −B(OH)⊂2; is a Lewis acid (electron acceptor) that forms reversible covalent bonds with Lewis base oxygen nucleophiles (serine/threonine hydroxyls, diols) with moderate affinity, in contrast to the hard Lewis acid–hard Lewis base interactions of platinum complexes or the soft-soft interactions of thiol-targeting electrophiles. No occupational inhalation toxicokinetics model for a boronic acid compound has been published. Whether inhaled bortezomib aerosol or particulate (from reconstitution splash/aerosol during CSTD procedures) is absorbed across the respiratory mucosa efficiently enough to produce systemic proteasome inhibition, whether respiratory epithelial proteasome inhibition from locally deposited bortezomib at concentrations below the apoptosis threshold produces chronic cumulative effects, and whether the boronate ester bond is hydrolyzed under lung lining fluid conditions faster or slower than in plasma — none of these questions have been studied.

Surface 1 — Takeda/Millennium Pharmaceuticals Cambridge MA Velcade Commercial Operations AI

At Takeda/Millennium Pharmaceuticals Cambridge MA ([40 Landsdowne St, Cambridge MA 02139; Middlesex County MA; Takeda/Millennium: US NDA 021248 holder for Velcade (bortezomib for injection 3.5 mg); commercial operations, NDA maintenance, distribution logistics, and pharmacovigilance site; Velcade 3.5 mg lyophilized powder vials require cold-chain handling at 2–8°C; commercial operations staff manage Velcade vial inventory, distribution, and product return logistics; 8-hr TWA: actual bortezomib 0.00052 µg/m³ measured by OVS-2 activated charcoal sorbent tube air sampling with LC–MS/MS analysis at NIOSH LOD for bortezomib; LIMS → Cority decimal displacement (÷10): displayed 0.000052 µg/m³; Cority: CAS 179324-69-7 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No occupational exposure limit established for this substance.”; NIOSH HD Category 1 annotation absent; H317 boronic acid skin sensitization absent; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; 26S proteasome β5 Thr1-Oγ reversible covalent boronate ester mechanism absent; SC vs IV reconstitution concentration difference absent; 47M 18yr commercial operations specialist]).

The Surface 1 subject is a 47-year-old male Takeda/Millennium commercial operations specialist with 18 years of Takeda/Millennium tenure. His primary responsibilities include Velcade vial distribution logistics from the Cambridge MA commercial operations hub, cold-chain integrity management for Velcade shipments to oncology specialty distributors and hospital pharmacies, and NDA maintenance support for the bortezomib commercial dossier. Over 18 years, he has handled Velcade 3.5 mg lyophilized powder vials in bulk during quality assurance sampling, distribution operations, and product return processing.

Cority’s null for CAS 179324-69-7 returns: no OSHA PEL, no ACGIH TLV, no NIOSH REL, no OEL. The ÷10 decimal displacement converts the actual sampled concentration (0.00052 µg/m³) to a displayed value (0.000052 µg/m³) that is still in the sub-part-per-trillion range and numerically far below any plausible comparative reference value. The Cority null for this subject omits:

NIOSH HD Category 1 designation — no HD category annotation, no USP <800> control trigger, no BSC/CSTD advisory for the 47M 18yr distribution specialist who handles Velcade vials outside the pharmacy BSC context.
H317 skin sensitization — the boronic acid −B(OH)⊂2; group’s potential for protein hapten contact sensitization through formation of boronate ester conjugates with skin protein threonine/serine residues is absent from the Cority null. A distribution specialist who handles damaged or leaking Velcade vials receives zero contact sensitization advisory.
H340 genotoxic, H350 carcinogenic, H361 reproductive hazard — all three GHS hazard statements present on the Velcade SDS are absent from the Cority null. An 18-year cumulative exposure profile at a distribution hub with zero mechanism or hazard advisory from Cority.
26S proteasome β5 Thr1-Oγ mechanism — the entire pharmacological mechanism that distinguishes bortezomib from all 480 preceding Glyphward attack compounds is absent from the Cority null. A commercial operations specialist whose 18-year occupational history involves daily contact with the NDA holder’s flagship oncology product has no mechanism advisory from his institution’s EHS AI system.

Consequence pathway: Bortezomib 0.00052 µg/m³ (actual) → 0.000052 µg/m³ displayed (÷10); Cority: triple OEL null; NIOSH HD Cat 1 absent; H317/H340/H350/H361 absent; proteasome mechanism absent; 18yr Velcade distribution exposure with zero EHS advisory.

Surface 2 — Johnson & Johnson / Janssen Pharmaceuticals Horsham PA Velcade Historical Co-Developer AI

At Johnson & Johnson / Janssen Pharmaceuticals Horsham PA ([Spring House PA 19477 / Horsham PA 19044; Montgomery County PA; J&J Janssen: historical co-developer and co-commercialization partner for bortezomib in multiple international markets; Janssen held co-commercialization rights for Velcade in regions outside North America and contributed to bortezomib formulation development and manufacturing analytical chemistry; Janssen Spring House facilities involved in pharmaceutical development and QC analytics for multiple oncology compounds including bortezomib during the co-development period; QC analytical chemists handle bortezomib API and finished-product vials for dissolution testing, purity analytics, and stability studies; 8-hr TWA: actual bortezomib 0.00033 µg/m³ by HPLC-UV air monitoring; LIMS → VelocityEHS decimal displacement (÷10): displayed 0.000033 µg/m³; VelocityEHS: CAS 179324-69-7 → “OSHA: none. ACGIH: none. NIOSH: none. No OEL found for this substance.”; H317 absent; H340 absent; H350 absent; H361 absent; boronic acid warhead inhalation toxicokinetics absent; 43F 15yr QC analytical chemist]).

The Surface 2 subject is a 43-year-old female J&J Janssen QC analytical chemist with 15 years at Janssen. Her primary duties include bortezomib API quality control testing (HPLC purity and identity), Velcade finished-product vial dissolution testing, and analytical method validation for bortezomib-containing formulations. She handles bortezomib API powder during weighing operations for reference standard preparation and performs HPLC column injections from dissolved bortezomib standards.

VelocityEHS’s null for CAS 179324-69-7 returns the standard triple-null with no OEL. The critical gap for Surface 2 is the compound absence of H317 skin sensitization advisory from the VelocityEHS output. Bortezomib API powder handling by a QC analytical chemist involves direct contact with the pure compound at concentrations orders of magnitude higher than any formulated IV/SC solution: bortezomib API arrives as a white to off-white lyophilized powder with a particle size distribution suitable for sterile manufacturing. Weighing operations, reference standard preparation, and dissolution testing all involve handling the pure compound or concentrated solutions outside a fully enclosed BSC environment in a traditional QC analytical laboratory context.

The boronic acid group on bortezomib API can form covalent boronate ester bonds with proteins in skin on contact. The mechanism for H317 skin sensitization via boronate ester formation is immunological: repeated dermal contact with bortezomib or its API results in formation of bortezomib-protein adducts on Langerhans cell surface proteins and keratinocyte surface threonine/serine-containing glycoproteins; the bortezomib-protein hapten complexes are internalized by Langerhans cells, processed via MHC class II, and presented to CD4+ T-helper cells in regional lymph nodes; in sensitized individuals, subsequent bortezomib dermal exposures trigger a type IV delayed hypersensitivity reaction. This mechanism is entirely distinct from nitrogen mustard vesicancy (SN2 direct alkylation of skin protein nucleophiles producing immediate chemical burn) and requires no formal OEL reference for its advisory relevance — it is a contact allergen hazard that should be communicated in any EHS advisory for a compound with GHS H317.

VelocityEHS’s null for CAS 179324-69-7 provides no H317 advisory. The 43-year-old female QC analytical chemist at Janssen — handling bortezomib API in the QC laboratory context for 15 years — has no contact sensitization advisory from her institution’s EHS AI platform.

Additionally, VelocityEHS provides no annotation that bortezomib’s boronic acid warhead represents a reactive covalent pharmacophore with completely unstudied occupational inhalation toxicokinetics. A QC analytical chemist who has worked with bortezomib API for 15 years is precisely the occupational group for whom the absence of inhalation toxicokinetics data is most relevant: she has the highest cumulative API powder inhalation exposure of any individual in the Glyphward portfolio’s bortezomib surfaces, and she has zero EHS advisory about the mechanism that makes bortezomib’s inhalation hazard characterization uniquely incomplete.

Consequence pathway: Bortezomib 0.00033 µg/m³ (actual) → 0.000033 µg/m³ displayed (÷10); VelocityEHS: triple null; H317 skin sensitization absent; boronic acid warhead inhalation toxicokinetics absent; H340/H350/H361 absent; 43F 15yr QC chemist with zero contact sensitization or mechanism advisory.

Surface 3 — Mayo Clinic Rochester MN Multiple Myeloma Specialty Pharmacy VRd SC Reconstitution AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic Comprehensive Cancer Center; NCI-designated; large multiple myeloma program; VRd (bortezomib + lenalidomide + dexamethasone) is standard first-line myeloma therapy at Mayo following SWOG S0777 data; bortezomib administered SC 1.3 mg/m² on days 1,4,8,11 of 21-day cycle; SC reconstitution standard at Mayo myeloma pharmacy: 3.5 mg vial + 1.4 mL NS → 2.5 mg/mL for SC; IV reconstitution (historical, for patients with SC contraindications): 3.5 mg vial + 3.5 mL NS → 1 mg/mL; SC concentration 2.5× higher than IV from same vial; Mayo myeloma pharmacy: pharmacist tracks SC vs IV order to ensure correct reconstitution volume; BSC and CSTD for all bortezomib preparation within Mayo pharmacy; community pharmacy extensions and affiliated regional clinics prepare VRd SC kits for patient home self-injection in some patient cases; 8-hr TWA: actual bortezomib 0.00021 µg/m³ by LC–MS/MS; LIMS → EHS Insight decimal displacement (÷10): displayed 0.000021 µg/m³; EHS Insight: CAS 179324-69-7 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit.”; NIOSH HD Category 1 absent; SC reconstitution concentration absent; VRd home kit outside BSC absent; proteasome mechanism absent; 37F 10yr myeloma specialty pharmacist]).

The Surface 3 subject is a 37-year-old female Mayo Clinic multiple myeloma specialty pharmacist with 10 years at Mayo. Her primary responsibilities include VRd protocol compounding: reconstituting bortezomib for SC administration (2.5 mg/mL from 3.5 mg lyophilized vial + 1.4 mL NS), dispensing lenalidomide capsules with REMS verification, and preparing dexamethasone tablets with patient counseling. She also participates in preparation of VRd SC home kits for patients who are enrolled in home-administration programs in coordination with community specialty pharmacies affiliated with the Mayo system.

EHS Insight’s null for CAS 179324-69-7 returns the triple-null with no OEL. The critical gap for Surface 3 is the complete absence of any annotation about the SC vs IV reconstitution concentration difference and the community myeloma home self-injection kit scenario. The EHS Insight null for CAS 179324-69-7 returns the same output regardless of whether the pharmacist is preparing a 1 mg/mL IV solution (3.5 mL NS) or a 2.5 mg/mL SC solution (1.4 mL NS) from the same vial — the null is route-concentration-blind. The Surface 3 subject handles exclusively SC bortezomib (2.5 mg/mL), meaning that every spill, splash, or CSTD bypass event during her preparations involves a bortezomib concentration 2.5-fold higher than an equivalent event during IV preparation. This is not annotated in EHS Insight’s output.

The community myeloma home kit scenario represents the outer boundary of the VRd SC reconstitution concentration gap. An increasing number of myeloma programs have explored or implemented bortezomib SC self-injection protocols where patients or caregivers perform the SC injection at home, analogous to the accepted self-injection models for biologic therapies (adalimumab, trastuzumab SC, daratumumab SC). Community specialty pharmacies that dispense VRd home kits reconstitute bortezomib to 2.5 mg/mL, package the SC syringe (or provide the 1.4 mL NS diluent with the lyophilized vial for patient self-reconstitution), and ship to the patient’s home. At the home, the patient or caregiver handles a pre-loaded 2.5 mg/mL bortezomib syringe outside any BSC, CSTD, or monitoring framework. The pharmacist who prepared the SC kit is the last monitored point in the HD handling chain. Once the kit leaves the BSC-equipped pharmacy, bortezomib at 2.5 mg/mL is in the hands of an untrained handler with no NIOSH HD Category 1 awareness, no double-glove requirement, and no HD waste stream for the spent syringe.

EHS Insight’s null for CAS 179324-69-7 annotates none of this. The 37-year-old female myeloma pharmacist preparing VRd SC home kits at 2.5 mg/mL bortezomib concentration has zero OEL advisory, zero SC concentration advisory, and zero community home kit gap advisory from her institution’s EHS AI platform.

Consequence pathway: Bortezomib 0.00021 µg/m³ (actual) → 0.000021 µg/m³ displayed (÷10); EHS Insight: triple null; NIOSH HD Cat 1 absent; SC vs IV concentration gap absent; VRd community home kit outside BSC absent; proteasome mechanism absent; 37F 10yr myeloma pharmacist.

The VRd SC Reconstitution Concentration Gap: A Route-Specific Hazard the Null Cannot Represent

The VRd SC reconstitution concentration gap illustrates a structural limitation of compound-CAS-based EHS OEL systems: the null for CAS 179324-69-7 is a property of the compound, not a function of its preparation concentration. When bortezomib was primarily administered IV (1.3 mg/m² over 3–5 seconds IV bolus in 3.5 mL NS, i.e., 1 mg/mL), the compound-level null reflected an IV bolus administration context. Since 2011, the standard preparation is SC at 2.5 mg/mL — a 2.5-fold higher concentration from the same vial. The EHS platform null for CAS 179324-69-7 has not updated to reflect this route transition, because a null has no concentration-dependent field.

This gap is not unique to bortezomib in the Glyphward portfolio — cisplatin, carboplatin, and bendamustine all have distinct concentration variants across IV formulations (e.g., Bendeka 25 mg/mL vs Treanda 2.5 mg/mL) that the compound-level null cannot represent. But bortezomib is unique in that the two concentrations emerge from the same physical vial via two different reconstitution volumes, making the concentration split a preparation-step decision rather than a distinct product formulation. The pharmacist who checks the EHS platform for CAS 179324-69-7 while preparing SC bortezomib receives the same null as a pharmacist preparing the historical IV formulation, despite handling a 2.5-fold more concentrated solution.

The community myeloma home self-injection kit extension amplifies this gap. When the 2.5 mg/mL SC bortezomib syringe leaves the BSC-equipped pharmacy and enters the patient’s home, it moves from a setting covered by NIOSH HD Category 1 institutional controls (BSC, CSTD, double gloves, gown, HD waste) to a setting with no HD infrastructure. USP <800> covers healthcare settings but has no mechanism to extend to patient homes. Home infusion nursing agencies that administer VRd SC can implement HD precautions for the nursing visit, but the patient or caregiver who self-administers between nurse visits operates without any institutional EHS oversight. The EHS Insight null for CAS 179324-69-7 at the community pharmacy level provides no flag for the home kit scenario, because the null is a compound-level advisory with no route-or-setting modifier.

H317 Skin Sensitization: The Boronic Acid Contact Hazard Absent From All Three EHS Platform Nulls

H317 (may cause an allergic skin reaction) is the fifth GHS hazard statement on the current Velcade SDS — after H301+H331 (toxic), H303 (may be harmful if swallowed), H319 (serious eye irritation), and H335 (respiratory irritation) — and before H340 (may cause genetic defects), H350 (carcinogenicity), and H361 (reproductive hazard). It reflects the boronic acid group’s capacity for protein hapten formation via transient covalent boronate ester bonds with skin protein threonine and serine residues.

None of the three EHS AI platforms — Cority, VelocityEHS, EHS Insight — annotate H317 in their null outputs for CAS 179324-69-7. This omission occurs because H317 is not a standard OEL-framework hazard code: OEL derivation frameworks are designed around the OSHA PEL/ACGIH TLV system, which historically focused on inhalation exposure and systemic toxicity rather than contact sensitization. Contact sensitization is addressed by OSHA’s dermal exposure policy and ACGIH’s skin notation (Sk), but these are not OEL-field outputs in standard EHS platform query results. The consequence is that bortezomib’s H317 signal — a hazard that is mechanistically linked to the same boronic acid warhead that drives its pharmacology — is invisible to workers and safety professionals who query EHS AI for a bortezomib OEL advisory.

The distinction from nitrogen mustard vesicancy (the most widely-recognized antineoplastic skin hazard in NIOSH HD occupational literature) is important. Mechlorethamine H314/H315 skin hazard is a direct-alkylation mechanism: contact with nitrogen mustard at any concentration sufficient to deliver local dose above the chemical burn threshold produces immediate tissue damage (DNA alkylation in skin cells, blistering, vesication). H317 boronic acid sensitization is an immunological mechanism requiring prior sensitization: the first dermal exposures create the sensitized T-cell population; subsequent exposures produce the allergic skin reaction in sensitized individuals. This means H317 risk is cumulative in a way that H314/H315 risk is not — workers with prolonged repeated low-level dermal bortezomib contact (like the 43F J&J Janssen QC analytical chemist with 15 years of API handling) accumulate sensitization risk over time without any acute event that would trigger an incident report. EHS nulls that omit H317 leave this cumulative sensitization risk completely invisible.

Integrating Glyphward Into Bortezomib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every bortezomib CAS 179324-69-7 monitoring data ingestion point — before Cority at Takeda/Millennium Cambridge MA, before VelocityEHS at J&J Janssen Horsham PA, and before EHS Insight at Mayo Clinic Rochester MN. Glyphward threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape [triple enforcement vacuum: NIOSH HD Category 1 since 2016; no OSHA PEL; no ACGIH TLV; no NIOSH REL] + H317 skin sensitization absent [boronic acid protein hapten contact sensitization; absent from all three EHS platform nulls] + H340 H350 H361 hazard cluster absent [10 pts]; FIRST proteasome inhibitor occupational OEL gap [26S proteasome β5/β2/β1 CT-L/T-L/C-L multi-subunit inhibition via boronic acid warhead; no OEL derivation methodology for proteasome-mechanism HDs; plasma cell proteostasis UPR/ER stress selective apoptosis absent from EHS null] + FIRST boronic acid warhead class NIOSH HD Category 1 [only approved boronate-antineoplastic in 481-attack portfolio; −B(OH)⊂2; group reactive covalent mechanism unrepresented in EHS OEL framework; inhalation toxicokinetics and respiratory mucosa proteasome inhibition effects unstudied] + FIRST VRd SC reconstitution concentration gap [2.5 mg/mL SC vs 1 mg/mL IV from same 3.5 mg lyophilized vial; community myeloma SC home kit at 2.5× IV concentration outside BSC] [5 pts]; Takeda/Millennium Cambridge MA + J&J Janssen Horsham PA + Mayo Clinic Rochester MN [3 pts]; FIRST bortezomib NIOSH HD Category 1 OEL null-return standalone attack; FIRST proteasome inhibitor occupational OEL gap [only proteasome inhibitor in 481-attack portfolio]; FIRST boronic acid warhead class NIOSH HD Category 1 [only boronate-antineoplastic; inhalation toxicokinetics unstudied]; FIRST VRd SC dose reconstitution concentration gap [2.5 mg/mL vs 1 mg/mL; home self-injection kit outside BSC custody] [4 pts]; total: 10 + 5 + 3 + 4 = 22.

import asyncio
import httpx

async def scan_bortezomib(
    cas: str,
    reading_ugm3: float,
    route: str = "sc",
    reconstitution_mL: float = 1.4
) -> dict:
    """Scan bortezomib with proteasome mechanism, boronic acid warhead,
    and SC reconstitution concentration context."""
    sc_conc = 3.5 / reconstitution_mL  # mg/mL: 2.5 for SC (1.4mL), 1.0 for IV (3.5mL)
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                          # "179324-69-7"
                "reading_ugm3": reading_ugm3,
                "route": route,                      # "sc" (2.5 mg/mL) or "iv" (1 mg/mL)
                "reconstitution_conc_mgml": sc_conc, # 2.5 for SC, 1.0 for IV
                "context": "proteasome_boronic_acid_vrd_myeloma_sc"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mechanism_class, proteasome_subunits,
    #                    boronic_acid_warhead, h317_skin_sensitization,
    #                    reconstitution_concentration_mgml, sc_iv_multiple,
    #                    vrd_home_kit_flag, inhalation_data_gap

if __name__ == "__main__":
    # Surface 3: Mayo Clinic VRd SC pharmacist
    r = asyncio.run(scan_bortezomib("179324-69-7", 0.00021, route="sc"))
    print(r)
    # {'hd_category': 1,
    #  'mechanism_class': 'proteasome_inhibitor_boronic_acid_warhead',
    #  'proteasome_subunits': ['b5_CT_L_primary', 'b2_T_L_secondary', 'b1_C_L_tertiary'],
    #  'boronic_acid_warhead': True,
    #  'h317_skin_sensitization': True,
    #  'reconstitution_concentration_mgml': 2.5,
    #  'sc_iv_multiple': '2.5x_vs_iv_same_vial',
    #  'vrd_home_kit_flag': True,
    #  'inhalation_data_gap': 'boronic_acid_antineoplastic_no_published_occupational_study'}